Download Wesley Research Institute

Wesley Research Institute
Annual Report
2011-2012
Mission
Immediate improvements in patient care and quality of life through medical research.
Vision
A leader in medical research acknowledged for achieving excellence and innovation in patient care. WRI fosters a
strong research culture in The Wesley Hospital, linking medical research and clinical practice. WRI is focused on
sustainable outcomes through collaboration with other stakeholders to maximise research benefits.
Differentiation
Working directly with patients, research by our clinicians is improving patient care and quality of life through:
• Faster, more accurate diagnoses
• Fewer, less severe side effects
• New treatments for faster, improved recovery
Major research areas
Cancer Cardiovascular
Diabetes
Men’s Health
Neurology
Nutrition
Rehabilitation
Respiratory
Seniors’ Health
Tissue Bank
Wound/Bone Healing
Women’s Health
Contents
Organisational Chart
3
Chairman’s Report
4
Director’s Report
5
UnitingCare Queensland Report
7
About WRI Research
8
Investigative Research Projects
9
Investigative Research Project Highlights
12
Clinical Trials Report13
Clinical Trials Highlights17
Data Management Office Report
19
Tissue Bank Report
20
Board of Directors21
Research Affiliations and Partners
24
Researchers25
Staff26
Patrons, Ambassadors and Committee
Members27
Supporters28
Naming Sponsors29
Community Engagement Activities
30
Financials32
Future33
3
WRI ANNUAL REPORT 2011-2012
Organisational Chart
Director
Chief Operations Officer
Accountant
Marketing
Coordinator
Accounts
Assistant
Fundraising
Officer
Research Liaison
Administrator
Clinical Data
Management
Officer
Tissue Bank
Manager
Data and IT
Services Officer
Business Development
Officer – Clinical Trials
Tissue Bank
Laboratory
Technician
Tissue Bank
Laboratory
Technician
Administration
Assistant
Senior Biostatistician
Data Management
Assistant
Clinical Research
Coordinator
Administration
Assistant
WRI Post-doctoral
Research Fellow Women’s Health
Clinical Data
Management
Assistant
Clinical Research
Coordinator
Xstrata Post-doctoral
Research Fellow
Clinical Research
Coordinator
WRI Research
Assistant
Clinical Research
Coordinator
WRI PhD Scholar
Clinical Research
Coordinator
WRI White Foundation
PhD Scholar
Clinical Trials
Centre Manager
Clinical Research
Coordinator
Clinical Research
Physician
Clinical Research
Physician
Clinical Trials Centre
Administration Assistant
4
WRI ANNUAL REPORT 2011-2012
Chairman’s Report
The Wesley Research Institute entrenched its reputation as a leading clinical research centre in 2011-12, tackling some
of the great health problems of the times and increasing its corporate and community relationships.
The Institute’s continuing high standard of research and the consequent
tangible results encouraged established corporate and philanthropic friends
to maintain and extend their support and attracted new ones to initiate
partnerships.
Mitsubishi Development continued that company’s remarkable record as WRI’s
longest standing corporate supporter. The Mitsubishi Development Rural and
Remote Health Centre pursued the long term goal of improving health care in
regional areas. This represents a major thrust for the WRI in the development
of internet based health programs through a growing range of collaborative
efforts utilising modern communications technologies that target contemporary
issues, including managing diabetes and promoting good nutrition.
Xstrata re-engaged with the WRI when Xstrata Copper committed to a major
research program focused on improving the health and wellbeing of the mining
workforce and regional mining communities.
QR National chose to partner WRI in order to further the company’s
commitment to better community health. The QR National support is being
applied to improving healthy living through research into cardiovascular
disease.
Ventyx (formerly Mincom) maintained its long term funding of the Ventyx
Wesley Research Institute Tissue Bank, whose growing repository of tissue and
blood samples is proving increasingly valuable to researchers of cancer and
other diseases. Several projects supported by the Institute are targeting ways
to prevent the spread of cancer.
A grant from international philanthropist Chuck Feeney, through Atlantic
Philanthropies, initiated a new level of research capability by the WRI some
seven years ago. The Queensland Government followed with decisive capital
that financed the current facilities, and the Government continues to provide
welcome operating funding. However, most of the research funding is sourced
from valued individual and corporate donors. The maintenance and growth of
WRI’s research effort depends overwhelmingly on the extent to which people,
businesses and governments contribute. Please take a moment to scan the list
of these wonderful supporters on page 28 of this report.
My heartfelt thanks are due to my fellow Board members for both the quality
and the extent of their efforts on behalf of the WRI during the year. I make
special mention of Deputy Chairman Peter Allen for his wise counsel and
demanding committee work he undertook during the year.
Teena Jameson retired from the Board in 2011 after nine years of service
during which the WRI benefited greatly from her outstanding marketing
experience. We were also most fortunate to have had the services of leading
medical practitioner and administrator Dr David Alcorn who retired in 2011 after
seven years as a Board Member.
A major task of the Board was the appointment of a successor to Professor
Julie Campbell as Director. One of Australia’s most highly regarded scientists,
Julie has provided the highest level of scientific and executive leadership of the
WRI for 16 of its 18 years. No one has contributed more than she has to the
success of the WRI in encouraging a culture of research at the Wesley Hospital,
in achieving recognition for scientific excellence and, most importantly, in
improving patient care.
Julie has led a team of exceptionally dedicated staff. We have also been
blessed with so many generous and helpful volunteers and donors. All this
wonderful effort has been channelled into support for the researchers who
deliver the outcomes that are described with pride and optimism in this report.
WRI ANNUAL REPORT 2011-2012
5
Director’s Report
This will be my last report as, after 16 years as Director, I will retire from the Wesley Research Institute (WRI) at the end
of 2012. My retirement will come nearly 40 years as a medical research scientist at universities / medical research
institutes in Sydney, Melbourne, London, Seattle, Geneva and Brisbane.
I retired as a NHMRC Senior Principal Research Fellow at the University of
Queensland (where I led a research group of up to 18 scientists in the field
of vascular cell biology) at the end of 2011, and now complete my retirement
by standing down from the WRI as well. My time at WRI has been particularly
satisfying, playing a role in ensuring that advances in medical science are
translated into improvements in health care for patients.
As in past years, 2011/12 has been a very busy time for WRI, with a large
number of research projects carried out across three genre: ‘InvestigatorInitiated Research’, where the clinician devises an extensive project of major
clinical relevance that is usually in collaboration with a scientist; ‘Patient
Outcome/Clinical Improvement Research’, where the researchers are often
nurses or allied health professionals and the results of the study lead directly to
improvements in patient care; and ‘Clinical Trials,’ usually funded through large
pharmaceutical companies, examining the efficacy of new drugs/vaccines or
medical devices on human volunteers.
To illustrate the work of the WRI, I will highlight just two of our InvestigatorInitiated projects and their relevance:
The first involves more accurate diagnosis of prostate cancer. One in 6 men
will be diagnosed with clinical prostate cancer in their lifetime. Currently,
digital rectal examination - which only detects advanced cancers; a blood
test measuring the level of Prostate Specific Antigen (PSA) – which has a low
specificity for prostate cancer; and ultrasound guided biopsy (TRUS) – where
the target tumour is mostly invisible; are used as diagnostic tools. This clinical
study is assessing the accuracy and reliability of multi-parametric Magnetic
Resonance Imaging (mpMRI) of the prostate as a first investigation of choice in
those patients with a raised PSA who, under current guidelines, would proceed
immediately to TRUS-guided biopsies of the prostate. This investigation aims
to prove scientifically that mpMRI of the prostate and MR guided biopsies
performed and read by uro-radio-pathological teams, will decrease the number
of men who need biopsies by 50%; decrease the number of biopsy needles
from 12 to 3; decrease the under assessment of aggressive tumours from
approx 50% to 5%; and decrease the unnecessary treatment of clinically
insignificant prostate cancers by approximately 70%.
experience symptoms of physical fatigue that impact on their overall ability
to undertake routine daily activities. These patients have a greater need
for nursing interventions and community support services. This study is
comparing the levels of fatigue, activity and quality of life in patients with ESKD
who are receiving either haemodialysis or haemodiafiltration treatment. Both
haemodialysis and haemodiafiltration are long established treatment options
for ESKD. The difference is that haemodialysis removes small molecular
weight waste substances from the blood while haemodiafiltration removes
both small and middle molecular weight waste products. Currently only 5%
of ESKD patients receive haemodiafiltration as opposed to haemodialysis due
to its higher treatment costs, even though it has better cardiovascular stability
during dialysis and improved patient survival. If it is shown to also substantially
improve patients’ quality of life, it may be more commonly prescribed.
Another Patient Outcome Improvement project aims to assist patients who
have had to be intubated and mechanically ventilated. It will determine when
is the right time to remove the external ventilation tubes from patients without
harm to allow them to breathe on their own. Currently the most effective and
accurate predictive indicator is the patient’s Rapid Shallow Breathing Index
(RSBI). We evaluate another parameter of the patient - the partial pressure of
carbon dioxide (PaCO2) divided by the minute volume (MV) - as a predictor
of extubation tolerance, and compare it to the current gold standard and to
patient outcome. If the new weaning index is more accurate than the current
procedure it will be incorporated into routine care in the Intensive Care Unit at
The Wesley Hospital. (Continued)
The second project I will highlight concerns cardiac amyloidosis (extracellular
deposition of insoluble fibrillar protein in the heart), which has an extremely
poor prognosis without treatment and after standard therapies. However,
our researchers have shown resolution of the process with a significant
improvement of survival after high dose chemotherapy and bone marrow
transplantation. They are now assessing the MRI characteristics of the hearts
of patients with cardiac amyloidosis who have undergone (or will undergo)
chemotherapy and bone marrow transplantation in order to determine whether
there are changes that predict which patients respond to this therapy. This
study will provide new knowledge regarding the cardiac changes in amyloidosis
and also give the clinicians information on who is likely to respond well to this
new treatment regime.
Our Patient Outcome / Clinical Improvement Research is likewise of major
importance. For example, one project aims to improve the life of patients
with end stage kidney disease (ESKD). More than 90% of people with ESKD
Image credit: Lorna Sim / AAMRI
6
WRI ANNUAL REPORT 2011-2012
Director’s Report continued
The WRI Clinical Trials Centre is also extremely busy and is currently
undertaking 22 clinical trials of which the following two are examples.
The first aims to improve the quality of life of patients with Multiple Sclerosis
(MS) by assessing the safety and tolerability of a new drug (prolonged-release
fampridine) in patients, and to determine how long-term use of this drug may
affect their quality of life and performance of daily activities. Fampridine acts
by improving impaired nerve conduction and represents a novel treatment
to improve walking impairment, a prominent manifestation of MS. With the
exception of anti-spasticity agents, no functional modifying therapies are
currently available to treat walking impairment. Walking disability is ranked by
both MS patients and neurologists as having the greatest negative impact on
quality of life.
A second clinical trial is investigating a new drug for the prevention of stroke
in atrial fibrillation (AF) patients. AF is the most common serious chronic
arrhythmia globally. Its prevalence increases with advancing age, affecting
more than 10% percent of persons aged 80 or older, and thus is expected
to double in the next 25 years as the population ages. The most important
complication of AF is stroke, the risk of which is increased five-fold in patients
with AF. This clinical trial compares the effect of a new drug (Apixaban) with
acetylsalicylic acid (aspirin) in the prevention of stroke in AP patients who have
failed (or are unsuitable for) vitamin K.
dedication. I would also like to acknowledge our Chief Operations Officer, Dr
Greg Hafner, who has championed major reorganisations within the Institute
and done an excellent job in guiding its workings on a day to day basis. The
Clinical Trials, Tissue Bank, Data Management, Fundraising, Marketing, Finance,
Administration, Biostatistics and Research staff, as well as our wonderful
volunteers, have likewise worked exceptionally hard this year and I thank them
all. The WRI is also indebted to Professor Pam McCombe who will resign at the
end of the year as Chair of the Research Committee after 9 years at its helm,
with an additional 4 years as a member.
Thank you to our Board and its Chairman, Martin Albrecht AC, and to all
members of the WRI Research Committee and its subcommittee, the Patient
Outcome Research Committee chaired by Professor Patsy Yates. The
functioning of the Institute would not be possible without your superb honorary
contributions.
I think that these examples of our research projects highlight the extent and
relevance of the role that WRI plays in improving patient care through research.
And it doesn’t stop there! WRI’s Tissue Bank collects surgical specimens
(usually cancers) that are used by Queensland researchers to hunt for the
cause and cure of diseases, and our Data Management Office carries out
clinical audits on behalf of the Wesley Hospital.
A personal highlight and honour for me this year was being invited by Mr
Chuck Feeney of The Atlantic Philanthropies to organise and host a ‘Hooked on
Science’ tour of five Australian cities by the 2009 Nobel Laureate for Physiology
or Medicine, Professor Elizabeth Blackburn. Professor Blackburn is the only
Australian woman to date to have received a Nobel Prize. Her lectures were
designed to inspire young Australian high school students (particularly girls) to
wonder at the natural world and its workings and to encourage them to study
science at school and university. Professor Blackburn also honoured the WRI
by providing us with the only lecture to scientists and medicos during her tour.
This event was attended by the Governor General Ms Quentin Bryce, as well as
the Queensland Assistant Minister for Health, Dr Chris Davis.
Another highlight for me was to serve for a second year as President of
the Association of Australian Medical Research Institutes (AAMRI). This
organisation represents Australia’s 42 independent medical research institutes
and, amongst other things, it lobbies Government to provide opinions and
submissions on matters affecting the medical research and health sectors.
I would like to thank all WRI staff and researchers for the huge effort they
have made, not only in 2011, but throughout the 16 years of my Directorship. Particular thanks go to Ms Annette Ganter, who has been the Research Liaison
Administrator for the WRI for all this time, indeed 3 weeks longer than me. Together we have seen the WRI develop from one room in Moorlands House
and only 3 staff to its present state. In her resides much of the Institute’s
corporate memory, and many of its successes are due to her hard work and
Prof Julie Campbell
When I retire as Director of the Wesley Research Institute at the end of 2012,
I will do so knowing that I have played an important role in guiding a fledgling
Institute in 1996 into the well-respected and widely known medical research
institute it is today. I hand over the reins to the new Director, Professor
Christian Gericke, in the knowledge that the Institute is in excellent condition
with wonderful staff to support its further development and expansion.
WRI ANNUAL REPORT 2011-2012
7
UnitingCare Queensland Report
Once again, the Wesley Research Institute has had another extremely productive year in seeking to make improvements
to the health and wellbeing of people “right now” as well as conducting clinical trials and innovative research that will
make a real difference to patient care and the quality of life for future generations.
This focus on conducting research that makes a real difference to people’s
lives aligns well to UnitingCare Queensland’s key strategic objective of being a
leader in people-centred care. Innovation, excellence, collaboration with others,
linking medical practice to clinical research, all speak to this important goal.
Now well established on the 8th floor of The Wesley Hospital’s new East Wing,
WRI researchers have been more easily able to work collaboratively with
clinicians at The Wesley Hospital which has enhanced existing constructive
partnerships, helped forge new ones and increased opportunities to achieve
better outcomes for patients.
We congratulate WRI on this and its many other achievements this year,
including around 50 investigative and patient-outcome research projects and
the continuing work of the Ventyx WRI Tissue Bank as it approaches a collection
of 25 000 samples from consenting patients at The Wesley Hospital undergoing
surgical procedures to remove tumours and other tissue.
We acknowledge and applaud all the researchers involved in the pioneering
work that has been conducted this past year and congratulate and thank WRI
Director Professor Julie Campbell AO and WRI Chair, Mr Martin Albrecht AC for
their commitment and passion to the work of WRI.
The Wesley Hospital is part of UnitingCare Health, which with UnitingCare
Community (Previously Lifeline Community Care Queensland) and Blue
Care comprise UnitingCare Queensland; together we provide quality and
compassionate care to more than 14 000 people every day of the year.
This year was the first in which UnitingCare Health’s Executive Director, Mr
Richard Royle, was a member of the WRI Board. This appointment has served
to strengthen our already strong partnership and has helped us in our mission
to reach out, speak and care – particularly for people experiencing health
issues now and in the future.
A highlight this year was the announcement from Xstrata of a donation of
$900 000 over three years for rural and remote health research. This will
focus on the health and wellbeing of the mining workforce and regional
mining communities and will enable WRI to build on a lot of the work currently
underway in collaboration with researchers in the Mitsubishi Rural and Remote
Health Centre, improving the health of people in regional areas of Queensland,
using modern communications technologies, managing diabetes and promoting
good nutrition.
Ms Anne Cross
Chief Executive Officer
UnitingCare Queensland
Mr Richard Royle
Executive Director
UnitingCare Health
8
WRI ANNUAL REPORT 2011-2012
About WRI Research
WRI’s clinical and applied research aims to discover, test and refine new techniques for better diagnosis and treatment of
illness and disease, improving health care practices and quality of life for patients.
Wesley Research Institute provides a range of scientific services and
research opportunities.
WRI Research Support Services
• Funding research projects
• Scientific research plan assistance
• Biostatistical support
• Clinical trial services
• Data management
• Tissue banking
• Research education and training
Clinical Trials
WRI has a purpose-built Clinical Trials Centre providing extensive facilities,
resources and experience.
A clinical trial is a research study designed to test the safety and/or
effectiveness of drugs, devices, treatments, or preventive measures. These
trials are initiated and funded by commercial device or pharmaceutical
companies.
All trials are scientifically, ethically and legally approved to national and
international standards. This ensures the safety of participants, transparency of
research and the highest standard of outcomes and benefits to the community.
• Infrastructure (facilities and equipment)
Data Management
Investigative Research
WRI’s Investigative research activities are divided into two categories:
WRI’s Data Management Office offers a broad range of services
for WRI, The Wesley Hospital, UnitingCare Health and self-funded
projects including:
• Investigator-initiated research
• Database design and construction – including web access format
• Patient outcome research
• Data collection and entry
Investigator-Initiated Research
This is research that is submitted through our Research Committee by
clinicians or allied health professionals and is often in collaboration
with our scientific research partners. The research must be consistent
with the mission and vision of the Institute and have a strong ‘Wesley’
focus. Applications for grant funding in this category must pass through
a rigorous assessment by both our Research Committee and a panel of
independent external scientific experts in the field.
Patient Outcome Research
This research is overseen by the Patient Outcome Research Committee,
a sub-committee of the WRI Research Committee. It involves projects
relating to outcomes of patients within clinical practice (medical, nursing
and allied health) and all support services of The Wesley Hospital. These
are typically smaller projects that do not require the same level of
rigorous assessment and can accelerate important research directly onsite.
• Baseline statistical analysis, reporting and presentation
• Advanced statistical analysis
• Literature search and reporting
Tissue Banking
The Ventyx Wesley Research Institute Tissue Bank collects, processes and
stores tissue samples, blood and related clinical data from consenting patients
at The Wesley Hospital. It is the largest, state-of-the-art, bio-repository of its
type for human tissue and blood in Queensland.
Researchers who are a part of an ethically and scientifically valid research
project can apply to the Tissue Bank Management Committee for tissues vital
to their work.
The Ventyx WRI Tissue Bank is a member of the Australian Biospecimen
Network and the International Society of Biological and Environmental
Repositories. It adheres to the international standards set down in Good
Clinical Practice (GCP) and Good Laboratory Practice (GLP) guidelines.
It is also governed by the Ventyx WRI Tissue Bank Management Committee,
which is overseen by the UnitingCare Human Research Ethics Committee.
WRI ANNUAL REPORT 2011-2012
9
Investigative Research Projects
Investigator-Initiated Research
The following investigative research projects were conducted in the 2011-12 period.
Project
Number
Title
Lay Title
Research Category
2006-10
Identifying the molecular basis for osteosarcoma metastasis.
Preventing the spread of bone cancer.
Cancer
2006-26
The site and nature of the visual defect underlying amblyopia in
humans.
Understanding the pathology of a common eye
disorder of children.
Neurology
2007-07
Immune responses in stroke.
Immune response in stroke.
Neurology
2008-08
Postoperative enteral nutrition in patients with advanced epithelial
ovarian cancer.
Improving nutrition of patients with advanced
ovarian cancer.
Cancer, Nutrition,
Rehabilitation, Women’s
Health
2008-10
Prospective evaluation of lymphoedema among patients with
gynaecological cancer.
The onset and incidence of lymphoedema in
women with gynaecological cancer.
Cancer, Women’s Health
2009-01
Cellular mechanisms of peritoneal sclerosis.
Understanding why long-term dialysis in renal
failure patients commonly fails.
Renal
2009-02
Cognitive functioning after adjuvant chemotherapy for early breast
cancer – follow-up evaluation five years after treatment.
Long-term changes in cognition in women
treated for breast cancer.
Cancer, Women’s Health
2009-06
Maintaining lean body mass in women with breast cancer without
gain – a pilot study.
Preventing fat gain after breast cancer
treatment.
Cancer, Nutrition,
Women’s Health
2009-16
Prevalent microorganisms detected in the female upper genital
tract: the effect of these microorganisms on oocytes in vivo and in
vitro and on outcomes.
Helping infertile women achieve successful
assisted reproduction treatment.
Women’s Health
2009-19
Executive dysfunction, perceived quality of life and CPAP treatment
effects in obstructive sleep apnoea patients.
Helping patients with sleep apnoea to function
better.
Men’s Health, Respiratory,
Women’s Health
2009-20
Hyperbaric oxygen radiation tissue injury study
“HORTIS” – Phase II.
Hyperbaric oxygen therapy to prevent damage
following radiation treatment for cancer in the
neck and pelvic regions.
Cancer, Men’s Health,
Women’s Health, Wound/
Bone Healing
2010-01
A Phase II randomised controlled trial of Plasmalyte 148 vs
bicarbonate as pump prime during cardiopulmonary bypass.
Preventing perfusion-induced inflammation
during heart operations.
Cardiovascular, Men’s
Health, Women’s Health
2010-03
Predicting recovery of language and communication after stroke
using neuroimaging.
Recovery of speech after stroke or other brain
injuries.
Neurology
2010-04
Improved treatment outcomes for breast cancer patients through
protein-based diagnosis with IGF family biomarkers.
Predicting breast cancer progression.
Cancer, Women’s Health
2010-09
Genetic analysis of colorectal cancer tumour-initiating cells.
Identifying the cells that initiate colorectal
cancer.
Cancer
2010-16
Evaluation of a telehealth support system to improve selfmanagement of physical activity and nutrition in people with Type 2
diabetes.
Delivering self-help to diabetics in rural and
remote areas.
Diabetes, Men’s Health,
Women’s Health
10
WRI ANNUAL REPORT 2011-2012
Investigative Research Projects continued
Project
Title
Number
Lay Title
Research Category
2011-03
Endometriosis risk: defining risk mechanisms for two
novel loci.
Understanding the genetic events that
cause endometrial cancer.
Women’s Health
2011-06
Establishment and genomic characterization of endometrial cancer
tumorgrafts for subsequent preclinical validation of molecularly
targeted therapeutic molecules.
Predicting the best treatment option for
individual patients with endometrial cancer.
Cancer, Women’s Health
2011-10
The nature, prevalence and impact of sleep disturbance in caregivers
of people with dementia.
The effect of dementia on caregivers.
Seniors’ Health
2011-11
A preliminary analysis of The Wesley Hospital 2010 Gynaecology
Service data: a study of unplanned returns to theatre, unplanned
readmissions, and post-operative bleeding complications.
Improved outcomes for gynaecology
patients.
Women’s Health
2011-15
An RCT to determine the effectiveness of hyperbaric oxygen therapy
for healing chronic venous leg ulcers: A randomised, double blind,
placebo-controlled trial.
The effectiveness of hyperbaric oxygen
therapy (HBOT) for healing chronic venous
leg ulcers.
Wound/ Bone Healing
2011-17
Examination of the expression and potential role of cancer associated
viral sequences in the causation and outcomes of breast cancer
patients.
Viruses as a cause of breast
cancer?
Cancer, Women’s Health
2011-21
The return of the normal heart – an MRI analysis of resolution
of cardiac amyloidosis after chemotherapy and bone marrow
transplantation.
Predicting response to a new treatment for
cardiac amyloidosis.
Cardiovascular
2011-ARC
(A)
Modelling and characterisation of beams used in radiotherapy.
More accurate beams for radiotherapy.
Cancer
2011-ARC
(B)
Chemical inhibition: a new approach to investigate the role of a key
protease, CtHtrA, from Chlamydia trachomatis.
Preventing infertility due to prolonged
infection by Chlamydia.
Women’s Health
2011NHMRC
Macrophages: a therapeutic target in peritoneal dialysis-induced
fibroses?
Preventing complications for dialysis
patients.
Cardiovascular, Renal
2012-03
The reconstruction of large segmental bone defects using patientspecific tissue engineered constructs.
Repairing large defects in bone.
Men’s Health, Women’s
Health, Wound/ Bone
Healing
2012-10
Xstrata Copper: medical research program.
Improve health and quality of life of current
and retired mining company employees.
Men’s Health,
Rehabilitation,
Rural/ Remote Health,
Women’s Health
Competitive Federal Government Grants
Australian Research Council – Linkage Project (QUT)
Australian Research Council – Linkage Project (QUT)
Chemical inhibition: a new approach to investigate the role of a key protease,
CtHtrA, from Chlamydia trachomatis.
– Dr Wilhelmina Huston, Dr John Allan
Modelling and characterisation of beams used in radiotherapy.
– Dr Jamie Trapp, Dr Richard Knight, Dr Tanya Kairn, Prof Christian Langton
National Health and Medical Research Council (UQ)
Macrophages: a therapeutic target in peritoneal dialysis induced fibrosis?
– Prof Julie Campbell, Dr Barbara Rolfe
WRI ANNUAL REPORT 2011-2012
11
Patient Outcome Research
Project
Title
Number
Lay Title
Research Category
2009-21 The body composition, nutritional status and quality of life of
patients undergoing stem cell treatment – a pilot study.
Improving the quality of life of cancer patients.
Cancer
2009-24
Assessment of lifestyle modification and compliance with risk factor
management with and without cognitive behavioural therapy (CBT)
intervention of cardiac patients 6, 12, 24 months post event.
Lifestyle modification helping heart attack
patients.
Cardiovascular,
Rehabilitation
2011-04
Anatomical and MRI presentation of the perineal body in women
undergoing prolapse surgery for posterior vaginal compartment
prolapse.
Description and incidence of three different
types of pelvic organ prolapse in women.
Women’s Health
2011-07
Retrospective assessment of the efficacy and safety of Aprotinin
and Tranexamic Acid in the management of bleeding during cardiac
surgery.
Assessment of two drugs in the management
of bleeding during cardiac surgery.
Cardiovascular
2011-09
A pilot study to compare the levels of fatigue, activity and quality
of life in people with end stage kidney disease (ESKD) who are
receiving either haemodialysis (HD) or haemodiafiltration (HDF)
treatment.
Improving the quality of life of patients with
renal failure.
Men’s Health, Renal,
Women’s Health
2011-12
Isolation and identification of microorganisms in human Fallopian
tubes, tubal ectopic pregnancies.
Identification of the micro-organisms that
contribute to ectopic pregnancies.
Women’s Health
2011-13
MRI and ultrasound characterisation of patella dislocation pre- and
post-medial patellofemoral ligament reconstruction.
Repairing recurrent dislocation of the patella.
Wound/ Bone Healing
2011-14
An observational study measuring the Free Plasma Cortisol levels in
Chronic Renal Failure Patients Undergoing dialysis – pre, post and
during dialysis and also in the dialysate.
Potential changes in cortisol levels during
renal dialysis.
Renal
2011-19
Isolation and identification of microorganisms in human endometrial
curettings, the Fallopian tube fimbriae and the peritoneal cavity
(ovarian surface) in women suffering from heavy (menorrhagia),
painful (dysmenorrhoea) menstrual cycles.
Is heavy and/or painful menstruation in
women associated with the presence of
micro-organisms in the upper genital tract?
Women’s Health
2011-05
Investigation of the impact of Intradialytic exercise with post
exercise supplement/snack on fatigue, quality of life, body
composition, function and energy/protein intake.
Improving the health and well-being of
haemodialysis patients.
Nutrition
2012-04
Predicting the success of extubation in mechanically ventilated
patients.
Knowing the right time to remove external
ventilation tubes from patients without harm.
Respiratory
12
WRI ANNUAL REPORT 2011-2012
Investigative Research Project Highlights
A potential marker and drug
target for colorectal cancer.
Background
Cancer patients often die because the tumour has
spread to other parts of their body.
The Project
WRI is collaborating with the Mater Medical
Research Institute including Wesley Hospital
colorectal surgeons, Dr John Lumley and Dr Brian
Meade, together with scientist Dr John Hooper,
to investigate how and why cancers, particularly
colorectal cancers, spread.
Repairing recurrent
dislocation of the knee cap.
Background
Dislocation of the patella (knee cap) is a
common cause of knee pain and dysfunction,
with up to 44% of patients having recurrent
instability following nonoperative
management of the initial dislocation. The
recurrent instability is caused by deficiencies
in the bone and in the attaching ligaments and
muscle.
The Project
They have developed an assay that detects this
protein in patient blood, then used the assay
to measure the levels of CDCP1 in the blood of
colorectal cancer patients to determine whether
CDCP1 can be used as a marker (diagnostic) for
this disease.
In collaboration with University of Queensland,
the researchers are using magnetic resonance
imaging (MRI) and ultrasound to image the
knees of patients presenting with recurrent
patella instability, in order to evaluate the
pathology of the instability and its effects on
the biomechanics of the knee joint. Also being
examined is whether recurrent instability of the
patella leads to osteoarthritis of the knee. A
sub-set of these patients who have undergone
surgical reconstruction to repair their dislocated
kneecap is included in the study to determine
whether the mechanics of the joint are restored
to pre-injury level by the operation.
Benefit
Benefit
While more work still needs to be done, the study
could result in earlier diagnosis of colorectal
cancer. Also, CDCP1 may prove to be a useful
target for inhibiting the spread of cancer cells
that are in the bloodstream after a patient has
undergone surgery to remove a primary tumour.
This comprehensive structural characterisation
of the unstable patello-femoral joint by MRI and
ultrasound imaging will play an important role
in determining the necessity, or otherwise, of
surgical reconstruction for this condition.
The researchers knew that a cell surface protein
called CDCP1 helps cancer cells to spread by
allowing them to evade death and they escape
from blood vessels.
Modelling and
characterisation of radiation
beams used in radiotherapy.
Background
WRI is a partner in a project that recently
secured competitive funding from the
Australian Research Council by Radiation
Oncology Medical Physicists, Dr Richard
Knight and Dr Tanya Kairn from Premion at
The Wesley Hospital, and Dr Jamie Trapp and
Professor Christian Langton, physicists from the
Queensland University of Technology.
The Project
The project will address a major challenge
of radiotherapy treatment which is to deliver
a radiation dose that ensures the whole of
a tumour is irradiated while simultaneously
avoiding or minimising irradiation of
neighbouring healthy tissue; this is particularly
difficult to achieve when a tumour has an
irregular shape or when critical structures are
located within very close proximity.
The researchers will use computer modelling
of radiation fields in radiotherapy to investigate
and improve their precision.
Benefit
It is expected that this will result in better
outcomes and fewer side-effects for
radiotherapy patients.
WRI ANNUAL REPORT 2011-2012
13
Clinical Trials Report
Research
Category
Trial
Title
Lay Title
ABSORB
A continuation in the clinical evaluation of the Abbott Vascular
Everolimus-Eluting Bioresorbable Vascular Scaffold in the
treatment of subjects with de novo Native coronary artery lesions.
The purpose of this trial is to assess the safety
and performance of a new investigational device
for the treatment of narrowed coronary (heart)
arteries.
Cardiology
ACUREST
Custom-fitting the mask – skin interface in continuous positive
airway pressure therapy: A randomised, best standard treatment
– controlled trial of compliance.
A study designed to assess the performance of a
new custom-fitted mask (TruFIT) versus the best
standard treatment mask in terms of compliance.
Respiratory
ALPHEE
Double-blind placebo controlled dose ranging study of the
efficacy and safety of Celivarone at 50, 100 or 300mg OD with
Amiodarone as calibrator for the prevention of ICD interventions
or death.
The purpose of this trial is to measure the effects
of 3 doses of celivarone 50, 100 and 300 mg
for the prevention of ventricular arrhythmia,
triggered by implantable cardioverter defibrillator
interventions or death.
Cardiology
ARISTOTLE A Phase 3, active (Warfarin) controlled, randomised, double-blind,
parallel arm study to evaluate efficacy and safety of Apixaban
in preventing stroke and systemic embolism in subjects with
nonvalvular atrial fibrillation.
This study is comparing a new medication
to standard treatment in the prevention of
stroke.
Cardiology
ARUBA A randomised multicenter clinical trial of unruptured brain
arteriovenous malformations.
The objective of this study is to compare
medical treatment as opposed to interventional
treatment in patients with malformed brain blood
vessels.
Neurology
ATMOSPHERE A multicenter randomised double-blind parallel group activecontrolled study to evaluate efficacy and safety of both aliksiren
monotherapy and aliskiren/enalapril combination therapy
compared to enalapril monotherapy morbidity and mortality in
patients with chronic heart failure (NYHA Class II-IV).
A study to assess whether aliskiren alone or
in combination with enalapril is safe and has
beneficial effects when added to standard
therapy in patients with chronic heart
failure. Cardiology
AVERROES
Apixaban versus Acetylsalicylic Acid to prevent stroke in atrial
fibrillation patients who have failed or are unsuitable for vitamin K
antagonist treatment: A randomised double-blind trial.
This study compares a new medication to aspirin
for the prevention of stroke in patients with atrial
fibrillation.
Cardiology
Baxter_ RRVV
A phase 3 study to assess the immunogenicity, safety, and
consistency of lot manufacture of Ross River Virus (RRV) vaccine
in healthy male and female subjects 16 years of age and older.
The purpose of the study is to evaluate the
efficacy, safety and consistency of manufacture
of 3 separate lots of inactivated RRV vaccine.
Vaccinology/
Immunology
14
WRI ANNUAL REPORT 2011-2012
Clinical Trials Report continued
Research
Category
Trial
Title
Lay Title
CAMMS323
A phase 3 randomised, rater-blinded study comparing two
annual cycles of intravenous Alemtuzumab to three-times weekly
subcutaneous Interferon Beta-1a (Rebif®) in treatment-naïve patients
with relapsing-remitting multiple sclerosis.
The objective of this study is to compare the
effect of a new medication to a currently
available treatment for multiple sclerosis.
Neurology
CAMMS324
A phase 3, randomised, rater- and dose-blinded study comparing
two annual cycles of intravenous low- and high-dose Alemtuzumab
to three-times weekly subcutaneous Interferon Beta 1a (Rebif®) in
patients with relapsing remitting multiple sclerosis who have relapsed
on therapy.
The objective of this study is to compare the
effect of a new medication to a currently
available medication for multiple sclerosis.
Neurology
CAMMS03409 An extension protocol for multiple sclerosis patients
who participated in Genzyme-Sponsored Studies of Alemtuzumab.
This research is being done to confirm and
extend the results of earlier studies.
Neurology
CARDIVA CE
Mark Study to demonstrate the safety and performance
of the Champion Vascular Closure System.
A study to test a new vascular closure device
that closes the hole left in the artery in the
groin when the angiogram procedure has
been completed.
Cardiology
CARIATIDE
An international, observational study to evaluate the impact of
educational material on the compliance and persistence rates to
Adjuvant Aromatase Inhibitor medication for postmenopausal women
with hormone sensitive early breast cancer. A study to evaluate the impact of educational
material on medication for postmenopausal
women with hormone sensitive early breast
cancer.
Breast Cancer
CHEST ICU
A multi-centre randomised controlled trial of fluid resuscitation with
starch (6% hydroxyethyl starch 130/0.4) compared to saline (0.9%
sodium chloride) in intensive care patients on mortality.
A study to find out whether critically ill adults
with low blood volume who receive fluid
resuscitation with a starch solution compared
to saline will have an improved chance of
survival 90 days later.
Intensive Care
CLIPPER HZC102970
A 52-week efficacy and safety study to compare the effect of three
dosage strengths of Fluticasone Fluroate/GW642444 Inhalation
Powder with GW642444 on the annual rate of exacerbations in
subjects with Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to look at the
effects of a combination of two experimental
inhaled medications in people with Chronic
Obstructive Pulmonary Disease over a year.
Respiratory
COHEREX A multi-center study to evaluate the safety and efficacy of the
Coherex Left Atrial Appendage Occlusion System.
A study to assess if the new Coherex Left
Atrial Appendage (LAA) Occlusion System is
safe and effective.
Cardiology
DARE
The impact of the intensive care discharge process on patients
outcomes study. The aim of this research is to determine
factors that may influence mortality and
readmission after discharge from ICU.
Intensive Care
DECIDE
Multicenter, double-blind, randomised, parallel-group, monotherapy,
active-control Study to determine the efficacy and safety of
Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon
ß-1a) in patients with relapsing-remitting Multiple Sclerosis.
A study to compare a new treatment with
Avonex in preventing relapse in patients
with MS.
Neurology
WRI ANNUAL REPORT 2011-2012
15
Research
Category
Trial
Title
Lay Title
EARLiMS
This research project aims to determine whether the new drug
fingolimod is more beneficial in people with relapsing-remitting
multiple sclerosis who have not been previously treated
compared with people who have been previously treated with
first-line therapies for this disease.
A multi-centre, open-label, non-randomised,
parallel group clinical trial to assess the efficacy
of fingolimod in naive patients versus fingolimod
in patients previously treated with interferons
or glatiramer acetate, based on the presence
of relapses in patients with relapsing-remitting
multiple sclerosis.
Neurology
ENABLE
Multicentre, multinational study to assess the effect of longterm prolonged-release Fampridine twice daily on quality of life
as reported by subjects with Multiple Sclerosis.
The purpose of the study is to collect information on
how long-term use of prolonged release Fampridine
may affect quality of life and performance of daily
activities.
Neurology
FREEDOM Future revascularisation evaluation in patients with diabetes
mellitus: optimal management of multivessel disease.
The purpose of this study is to compare two
different methods of treatment for patients with
diabetes and coronary artery disease, who require
coronary intervention.
Cardiology
GUARD
The genetic understanding of asbestos related diseases
(GUARD) study.
A study to investigate what role genetic and
environmental factors play in the development of
asbestos related diseases.
Oncology
INSOMNIA 009
A phase III, multicenter, randomised, double-blind, placebocontrolled, parallel-group, long term safety study of
MK-4305 in patients with Primary Insomnia.
A study to test the long term safety and
effectiveness of a new drug for patients with
Primary Insomnia.
Sleep Medicine
INSOMNIA 028
A phase III, multicenter, randomised, double-blind,
placebo-controlled, parallel group, study to evaluate the safety
and efficacy of MK-4305 in patients with Primary Insomnia –
Study A.
A study to test the safety and effectiveness of a new
drug for people with Primary Insomnia.
Sleep Medicine
PATENT I
Randomised, double-blind, placebo-controlled, multi-centre,
multi-national study to evaluate the efficacy and safety of oral
BAY 63 2521 (1mg, 1.5mg, 2mg, or 2.5mg tid) in patients with
symptomatic pulmonary arterial hypertension.
A study to evaluate a new drug for people with
pulmonary arterial hypertension.
Respiratory
PATENT II
Long-term extension, multi-centre, multi-national study to
evaluate the safety and tolerability of oral BAY 63-2521 (1mg,
1.5mg, 2mg, or 2.5mg tid) in patients with symptomatic
pulmonary arterial hypertension. A long term extension of Patent I study. A clinical
trial to evaluate a new drug for people with
pulmonary arterial hypertension.
Respiratory
PEGASUS
A randomised, double-blind, placebo controlled, parallel group,
multinational trial, to assess the prevention of thrombotic
events with Ticagrelor compared to placebo on a background
of Acetyl Salicylic Acid therapy in patients with history of
myocardial infarction.
A study to assess whether a new medication given
twice daily in addition to Acetysalicylic Acid (ASA)
therapy decreases the frequency of cardiovascular
events in patients with heart disease.
Cardiology
PREDICT Perceived risk of ischemia and bleeding in acute Coronary
syndrome patients.
The aim of this study is to look at how treating
physicians assess the risk of cardiovascular events
(such as stroke and heart attack) and adverse
events (such as bleeding) in patients with heart
attack. Cardiology
PROTECT Patient related outcomes with Endeavor versus Cypher stenting
trial.
A study to compare two different stents in patients
requiring stent implantation.
Cardiology
16
WRI ANNUAL REPORT 2011-2012
Clinical Trials Report continued
Research
Category
Trial
Title
Lay Title
RECORD Registry on cardiac rhythm disorders: an international,
observational, prospective survey assessing the control of atrial
fibrillation in Asia Pacific.
The purpose of this study is to assess the control
of atrial fibrillation over one year and to compare
the clinical outcomes in rhythm versus rate control
strategies.
Cardiology
SIGNIFY
Effects of ivabradine in patients with stable coronary artery
disease without clinical heart failure. A randomised double-blind
placebo-controlled international multicentre study.
A study to assess whether Ivabradine reduces
cardiovascular events in patients with stable
coronary artery disease without heart failure.
Cardiology
SNAC I A multi-centre randomised trial of sentinel lymph node biopsy
versus axillary clearance in operable breast cancer.
A study to compare surgical complications and
disease progression between two different
surgical procedures in the detection and removal
of cancer of the lymph nodes.
Breast Cancer/
Surgery
SNAC II
A multi-centre randomised trial of sentinel lymph node biopsy
versus axillary clearance in operable breast cancer (extension of
SNAC I).
This study is an extension to SNAC I and will
expand the inclusion to women who have larger
breast cancers and more than one breast
cancer.
Breast Cancer/
Surgery
SOLID A clinical outcomes study of Darapladib versus placebo in subjects
following acute coronary syndrome to compare the incidence of
major adverse cardiovascular events (MACE).
This trial will evaluate the clinical efficiency of a
new drug to treat patients after an acute coronary
syndrome.
Cardiology
SPIRIT PRIME
A Clinical Evaluation of the XIENCE PRIME ™ and XIENCE PRIME
™ LL Everolimus Eluting Coronary Stent System.
The purpose of this study is to evaluate if
the drug-coated stent is a safe and effective
treatment for the blockage and narrowing of heart
arteries.
Cardiology
SORE THROAT
A multi-centre, randomised, double-blinded, placebo-controlled,
parallel group,multiple dose, study of the efficacy of 8.75
mg flurbiprofen spray in the relief of sore throat due to upper
respiratory tract infection.
The purpose of this study is to test the
effectiveness of a new product developed for
the treatment of sore throat called flurbiprofen
spray.
Respiratory
STABILITY
A clinical outcomes study of Darapladib versus placebo in subjects
with chronic coronary heart disease to compare the incidence of
major adverse cardiovascular events.
This new study drug will assess people who
have had a heart attack and aims to reduce a
reoccurrence.
Cardiology
TERACLES
A multi-centre double-blind parallel-group placebo-controlled
study of the efficacy and safety of Teriflunomide in patients with
relapsing multiple sclerosis who are treated with Interferon-Beta.
Test the effect of a new medication in comparison
to placebo on the frequency of MS relapses
in patients with relapsing forms of MS already
treated with Interferon-Beta. Neurology
THERAVIDA
201-002
(Overactive
Bladder Study)
Comparison of THVD201, a Combination of Tolterodine and a
Muscarinic Agonist vs. Tolterodine Alone vs. Placebo in subjects
with overactive bladder symptoms.
The purpose of this study is to assess the
tolerability and side effects of a new combination
medication in patients with overactive bladder
symptoms.
Urology
VERVA A randomised, placebo-controlled, double-blind trial to assess the
safety and glucose-lowering efficacy of VVP808 in participants
with Type 2 diabetes.
A study to test an experimental treatment in order
to reduce glucose levels in people with Type 2
diabetes. Endocrinology
XAMOS
Xarelto in the prophylaxis of post surgical venous
thromboembolism after elective major orthopedic surgery of hip
or knee.
An observational study designed to obtain data
on the use of rivaroxaban and other drugs in the
prevention of venous thromboembolism (VTE) in
elective hip or knee surgery in clinical practice.
Orthopaedics
WRI ANNUAL REPORT 2011-2012
17
Clinical Trials Highlights
ENABLE
Multicentre, multinational study to assess the effect of long-term
prolonged-release fampridine twice daily on quality of life as
reported by subjects with Multiple Sclerosis.
Background
Multiple Sclerosis (MS) is a disease of the central nervous system and usually
presents unexpectedly through a variety of symptoms.
The purpose of the study is to collect information on how long-term use of
prolonged release Fampridine may affect quality of life and performance of daily
activities.
Fampridine acts by improving impaired nerve conduction and represents a novel
treatment to improve walking impairment, a prominent manifestation of MS.
Walking disability is ranked by both MS patients and neurologists as having the
greatest negative impact on quality of life. With the exception of anti-spasticity
agents, no functional modifying therapies are currently available to treat walking
impairment.
The project
A study to assess the effect of a long-term medication treatment on quality of life
as reported by subjects with Multiple Sclerosis.
Benefit
This study will allow researchers to learn more about the safety of long-term
treatment with the investigational medication and to help improve the quality of life
in patients with MS.
18
WRI ANNUAL REPORT 2011-2012
Clinical Trials Highlights continued
SNAC II
A multicentre randomised trial of sentinel
node biopsy versus axillary clearance in
operable breast cancer.
Background
SNAC II is a study comparing surgical
complications and disease progression between
two surgical procedures in the detection and
removal of cancer of the lymph nodes.
Every year, more than 11,300 Australian women
are diagnosed with breast cancer. Most need
surgery to remove the cancer and determine
whether it has spread to the axillary lymph nodes.
The Project
This study is an extension to SNAC I and will
expand the inclusion to women who have larger
breast cancers and more than one breast cancer.
Benefit
This clinical trial will help women and surgeons
decide about the appropriateness of sentinel node
based management of the axilla in a wider range
of circumstances, and include women who have
larger breast cancers and more than one breast
cancer.
Sore Throat
A multi-centre, randomised, doubleblinded, placebo-controlled, parallel group,
multiple dose, study of the efficacy of
8.75 mg flurbiprofen spray in the relief of
sore throat due to upper respiratory tract
infection.
Overactive Bladder
TheraVida Overactive Bladder Comparison
of THVD-201, a Combination of Tolterodine
and a Muscarinic Agonist vs. Tolterodine
Alone vs. Placebo in Subjects with
Overactive Bladder (OAB) Symptoms.
Background
Background
This study will assess the safety and
effectiveness of flurbiprofen spray formulation
in patients with sore throat over a period
of three days. This is a new treatment for
throat soreness, sore throat relief, sore throat
pain intensity, swollen throat and difficulty in
swallowing.
An overactive bladder is a common problem
in women, causing a sudden and unstoppable
need to urinate even though the bladder may
only contain a small amount of urine.
A sore throat is a common physical symptom
usually caused by acute throat inflammation
and is one of the most common illnesses
seen in General Practice and Emergency
Departments throughout Australia.
It can cause mild to extreme pain and can be
very debilitating. Most sore throats are caused
by viruses and characterized by a rapid onset of
symptoms and typically the recuperation period
is relatively short.
The Project
The purpose of this study is to test the
effectiveness of a new product developed for
the treatment of sore throat called flurbiprofen
spray.
Benefit
This study will provide valuable data to support
a direct dose medication for the symptomatic
treatment of sore throat.
This study investigates the effects and safety
of a new medication on symptoms of an
overactive bladder, compared to tolterodine
alone and whether the combination treatment,
of tolterodine with pilocarpine added reduces
unwanted side effects (dry mouth).
The Project
The purpose of this study is to assess the
tolerability and side effects of a new combination
medication in patients with overactive bladder
symptoms.
Benefit
The benefit of the new medication or
combination treatment would most likely result
in patients continuing on therapy longer with
fewer side effects and as a result controlling
frequency, urgency and incontinence.
WRI ANNUAL REPORT 2011-2012
19
Data Management Office Report
The Data Management Office is proud to collaborate with The Wesley
Hospital and other independent researchers to assist in data collection
and analysis to establish industry benchmarking and improve clinical
practices in patient care.
The fourth annual Cardiac Audit was a key focus for the team during the
past year. It involved collecting and analysing clinical data within the hospital
to establish industry benchmarks, identify risk factors to ultimately improve
treatments, and reduce hospital length of stay for cardiac patients at The Wesley
Hospital.
The Audit encompassed:
• Database building
• Data collection from all the cardiac clinical areas
• Chart review of cardiac surgery
• Data entry
• Auditing services
• Analysing data
• Feedback to the Cardiology Craft Group
• Presentation of the yearly data at the annual audit dinner, hosted by The
Wesley Hospital
The following studies were also conducted throughout the 2011-12 financial
year:
• Clinical Outcome Improvement Research including the development of the
Prostate Database
• Patient Outcome Research, including Cardiac Surgery Bleeding Study, and
Sarcoidosis Study
20
WRI ANNUAL REPORT 2011-2012
Tissue Bank Report
Project title: Tissue requested: Investigator: Institution: The Ventyx (Mincom) WRI Tissue Bank had another
successful year, increasing the diverse collection of
normal and cancerous specimens from consenting
patients at The Wesley Hospital.
Highlights
• 482 donors provided consent for their samples to be banked for research bringing the total number of donors to 1582
• Additional surgeons and their staff have been recruited in areas of breast
and endocrine, gynaecology, gynaecological oncology, IVF, obstetrics,
orthopaedics, neurology and urology
• The Tissue Bank Management Committee reconvened with representation
from medical, research, bioethics, the public and legal sectors
• An international distribution agreement was signed with Bioserve
Supported Projects
From July 2011 to June 2012, the Ventyx WRI Tissue Bank has facilitated
the patient informed consent and recruitment, procurement, processing,
storage and distribution of samples with matched clinical data for the following
research projects:
Project title: ‘Molecular Pathology of Breast Tissue’
Tissue requested: Breast tissue
Investigator: Prof Sunil Lakhani
Institution: University of Queensland
‘Development of a new inhibitor compound to prevent Chlamydia trachomatis – related infertility’
Uterus, endometrium, ovarian tissue and bloods
Dr Wilhelmina Huston
Queensland Institute of Technology
Project title: ‘Endometriosis risk: defining risk mechanisms for two novel loci’
Tissue requested: Endometriosis tissue and bloods
Investigator:
Prof Grant Montgomery
Institution:
Queensland Institute of Medical Research
Project title: Tissue requested:
Investigator:
Institution:
‘Genetic Analysis of Colorectal Tumour Initiating Cells’
Colorectal tumour tissue, liver metastisis tissue, bloods, FFPE blocks and stained slides
Assoc Prof John Hooper
Mater Medical Research Institute
Project title: Tissue requested:
Investigator:
Institution: ‘Proximal Tubule epithelial cell transduction of protein overload into tubulointerstitial injury’
Normal kidney cortex tissue
Dr Ray Wilkinson
Queensland Institute of Medical Research
Project title: Tissue requested:
Investigator:
Institution: ‘Australian Prostate Cancer BioResource’
Prostate and blood
Dr Judith Clements
Queensland Institute of Technology
Project title:
Tissue requested: Investigator:
Institution:
‘Isolation and identification of microorganisms in human endometrial curettings, the Fallopian tube fimbriae and the perionteal cavity in women suffering from menorrhagia, dysmenorrhoea’
Uterus, endometrium and fallopian tube tissue
Dr Elise Pelzer
Wesley Research Institute and
Queensland Institute of Technology
WRI ANNUAL REPORT 2011-2012
21
Board of Directors
Mr Martin Albrecht AC, Chairman
Martin Albrecht has been Chairman of the Wesley Research Institute Board since 2004, and is a prominent
Australian businessman with a number of public and NGO appointments. Martin was Chairman of Thiess Pty Ltd
(having previously been the company’s Chief Executive) and a nonexecutive Director of Leighton Holdings Ltd. He is
currently Chair of Exergen Pty Ltd and has wide ranging government and community involvements.
Martin was made a Companion of the Order of Australia (AC) for service to the construction industry, export
markets, the engineering profession and the community. He has received the Australian Constructors Association
and QUT Distinguished Constructors Awards and Engineering Australia (Qld) and AICD Gold Medal Awards. He
has honorary Doctorates from the University of Queensland, QUT, Uni SA, Griffith, an Honorary Fellow of Engineers
Australia and is a recipient of the Centenary Medal.
Mr Peter Allen, Deputy Chairman
A WRI Director since 2005, Peter Allen is a consultant and former partner with the national law firm Allens
Linklaters and is a Notary Public. He is currently Chairman of the Neumann Group, Nucrush Group and
BioPharmaceuticals Australia (Network) Pty Ltd, a director of Ensham Workers Entitlement Fund Pty Ltd and The
Riverside Coal Transport Company Pty Ltd.
In the community, he is a past president of the MS Society of Queensland and the Revenue Law Committee of the
Queensland Law Society.
Dr John Allan
John Allan is the Director of the Wesley Reproductive Medicine and Gynaecological Surgery Unit and the Medical
Director of Wesley Monash IVF. John has been appointed the Inaugural Head of the Wesley St Andrews Clinical
School and is the Director of Medical Education at The Wesley Hospital. He is a member of the UnitingCare Health
Human Research Ethics Committee and he has an active participation in clinical research projects at WRI.
Mr Christopher Barnard
Chris Barnard is Executive Director of JBWere. He has been involved in the non-profit sector for over twenty years
having been a Director of Bluecare and Churches of Christ Care. He has chaired the Queensland Aged Care
Planning Advisory Committee for the Federal Government and is currently a committee member of Prince of Peace
Lutheran School College Council. Chris has a Bachelor of Business from QUT, an MBA from the University of
Queensland and a Graduate Diploma in Financial Planning.
Dr David Cross
David Cross is a cardiologist who practices at The Wesley Hospital and at Royal Brisbane and Women’s Hospital.
He has a longstanding interest in clinical trials research, and has been the principal investigator for many studies
conducted through the Wesley Research Institute. He has also been a member of the Research Committee of the
Wesley Research Institute since 1999.
David was one of the founding partners in Heart Care Partners in Brisbane which in turn was the initial practice in
the national Genesis Care group. He is a Graduate of the Australian Institute of Company Directors, and is a Director
of several private companies including Wesley Health Pty Ltd.
22
WRI ANNUAL REPORT 2011-2012
Board of Directors continued
Mr Paul Darrouzet
Paul Darrouzet has been the Chairman of the Lifestream Foundation since 2004. He has served as the Chairman
of Foxleigh Mining Pty Ltd, General Manager of Australian Bulk Minerals and Group Manager HR for Thiess
Contractors Pty Ltd. Paul has a Bachelor of Business from QUT and an active interest in medical research and
social responsibility. He joined the WRI Board of Directors in 2011.
Ms Teena Jameson (resigned December 2011)
Teena Jameson joined the WRI Board in 2002. Teena brings more than 30 years experience in marketing,
advertising and media. She is the Managing Director of Media Circus and former National Client Service Director
of the Mitchell Communication Group and founder and former Managing Director of Mitchell & Partners (Qld). In
addition, Teena has previously served as a Director of the Brisbane Festival.
Mr Collin Myers
A WRI Director since 2004, Collin Myers is an investor relations consultant with a strong background in media and
public affairs. Formerly a political reporter in Brisbane, Canberra and London, he worked as Senior Adviser to the
Australian Prime Minister and was MIM’s long time head of corporate affairs.
Collin serves as President of the Queensland Youth Orchestras and a Director of the Queensland Private Enterprise
Centre. He was formerly Chair of the Griffith University Business School Advisory Council, the Queensland College
of Art and the TN Theatre Company, Deputy Chair of the Brisbane Biennial Festival and a Director of the Royal
Queensland Bush Children’s Health Scheme and the National Heart Foundation.
Dr Luis Prado
Dr Luis Prado, Chief Medical Officer for UnitingCare Health and Director of Medical Services at The Wesley Hospital,
joined the WRI Board in 2007. He brings extensive health care experience both as a clinician and a manager.
Following early years in the Royal Australian Army Medical Corps, Luis held executive medical positions at The
Prince Charles Hospital and in the Sunshine Coast Health Services. Luis is Chair of Board of Directors of the
Postgraduate Medical Council of Queensland, a Director of Confederation of Postgraduate Medical Councils of
Australia and an Associate Professor of Bond University. He holds Fellowships of the Royal Australian College of
General Practitioners, Royal Australian College of Medical Administrators, the Australian College of Health Service
Management and the Australian Association of Quality in Healthcare.
Ms Jillian Richards
Jillian Richards has served as a WRI Director and Chairman of the Finance and Audit Committee since 2003. Her
focus is on overseeing the investment, accounting and financial reporting processes established by the Institute.
Jillian is a Partner with KPMG and understands the importance of corporate responsibility and medical research.
WRI ANNUAL REPORT 2011-2012
23
Mr Richard Royle
Richard Royle has more than 27 years experience in the healthcare industry including his current role as Executive
Director of UnitingCare Health. Other roles held by Richard include Strategic Funding Director for Medibank Private and
Director in a private consulting company specialising in health and aged care.
Richard was a founding Board member of Uniting Aged Care, Vic/Tas. He is Vice-President of the Australian Private
Hospitals Association. Towards the end of 2010, he was appointed as a Trustee Director of the Health and Community
Industries Fund (HESTA).
Mr Charlie Sartain
Charlie Sartain joined the WRI Board in 2009. A leading Queensland based mining industry figure, he is Chief
Executive of Xstrata Copper, a major global copper producer with operations in five countries. Charlie had a long career at
MIM Holdings prior to its acquisition by Xstrata in 2003, advancing through mining engineering and senior executive roles in
several mines in Queensland and at Minera Alumbrera in Argentina. He has led Xstrata Copper as its CEO since 2004.
Charlie is a member of the Executive Committee of Xstrata Schweiz AG, a Director of the International Copper Association,
a Senator at the University of Queensland, and a Director and Chairman of the Advisory Board of the Sustainable Minerals
Institute at the University of Queensland.
Prof Russell Stitz AM, RFD
Russell Stitz is a Senior Surgeon in the Colorectal Unit at the Royal Brisbane and Women’s Hospital (RBWH) and at
The Wesley Hospital and is an Adjunct Professor at the University of Queensland. He is currently the Health Quality
and Complaints Commissioner in Queensland and is Chairman of the National Lead Clinicians Group. He chairs
the Specialist Connect Board and has been the Professor of Clinical Surgery at RBWH and Head of the Surgical
Discipline for the University of Queensland (2008-2011). Recently he was appointed to the Health Care Committee
of the National Health and Medical Research Council (NHMRC).
After completing his surgical training at RBWH, he extended his experience in the United Kingdom where he trained
in Colorectal Surgery at St Mark’s Hospital, London. In 2001, he returned to the latter hospital as the Sir Alan Parks
Visiting Professor. He has been Chairman of the Section of Colon and Rectal Surgery of the Royal Australasian
College of Surgeons and is a Past President of the Colorectal Surgical Society of Australia and New Zealand. He
has been President of the Royal Australasian College of Surgeons (RACS), Chairman of the Committee of Presidents
of Medical Colleges (CPMC) and a Director of the Australian Medical Council. He has been a pioneer in the
development of laparoscopic colorectal surgery and has published and presented on many aspects of colorectal
disease.
24
WRI ANNUAL REPORT 2011-2012
Research Affiliations and Partners
WRI’s medical research programs would not be possible without the collaboration and support
of these partner organisations.
Research Affiliates
Clinical Trial Industry Sponsors
Briz Brain & Spine
Deakin University & Southern Health Service
Garvan Institute of Medical Research
Greenslopes Private Hospital
Griffith University
Haematology and Oncology Clinics of Australasia
HeartCare Partners
Mater Hospitals and Health Services
Mater Medical Research Institute
Premion
Princess Alexandra Hospital
Queensland Institute of Medical Research
Queensland Health
Queensland University of Technology
Royal Brisbane and Women’s Hospital
The Scripps Research Institute
The Wesley Hospital
University of Queensland
Wesley Breast Clinic
Wesley Centre for Hyperbaric Medicine
Wesley Medical Imaging
Abbott Cardiovascular Systems
AstraZeneca
Baxter
Bayer Healthcare
Biogen Idec
Bristol-Myers Squibb
Coherex medical INC
GlaxoSmithKline
Janssen Cilag
Medtronic
Merck Sharpe and Dohme
Novartis
PPD
Reckitt Benckiser
TheraVida, Inc
Professional Affiliations
Australasian Biospecimens Network
Australasian Health and Research Data
Managers Association
Australian Prostate Cancer BioResource
Australian Research Council
Association of Australian Medical
Research Institutes
Association of Regulatory and Clinical Scientists
International Society for Biological and
Environmental Repositories
Life Sciences Queensland
National Health and Medical Research Council
Queensland Clinical Trials Network
Research Australia
Research Ethics and Governance Unit,
Queensland Health
Clinical Trial Non-Industry Sponsors
Australian and New Zealand Intensive Care Unit
Clinical trials Group (ANZICU CTG)
Queensland Institute of Medical Research
National Heart Lung and Blood Institute
National Institute for Health
National Health and Medical Research Council
Royal Australasian College of Surgeons
The George Institute for Global Health
Clinical Research Organisations
Flinders Medical Centre
Gleneagles
ICON Clinical Research
INC Research
Novotech
Pacific Clinical Research Group
PRA International
Quintiles
PCRG
Worldwide Clinical Trials
Pathology Providers
Aquesta Pathology
Dorevich Pathology
Envoi Pathology
Sullivan Nicolaides Pathology
Queensland Medical Laboratory
WRI ANNUAL REPORT 2011-2012
25
Researchers
The following dedicated clinicians, allied health professionals and scientists have contributed to WRI’s research programs and clinical trials
throughout the past 12 months.
Investigatior-Initiated and
Patient Outcome Researchers
Ms Alicia Allan
Dr Janet Allan
Dr John Allan
Dr Roger Allen
Ms Brooke Andrew
Ms Merrilyn Banks
Dr John Bashford
Ms Lin Bates
A/Prof Judy Bauer
Dr Geoffrey Beadle
Prof Ken Beagley
Ms Emma Beckman
A/Prof Ian Bennett
Dr Paul Bennett
Prof Andrew Biankin
Dr Ann Bonner
Dr Rebecca Box
Prof Ian Brereton
Prof Melissa Brown
Ms Lyn Buller
Dr Paul Burrell
Dr Melissa Buttini
Dr Peter Cain
Ms Helen Callum
Prof Julie Campbell
Prof Sandra Capra
Ms Mandy Cassimatis
Mr Richard Clark
Mrs Melissa Clarke
Prof Judy Clements
Dr Andrew Clouston
Dr Chris Cole
A/Prof David Copland
Dr David Cross
Dr Paul Davies
Ms Sharyn Denmeade
Dr Ian Dickinson
Dr Ying Dong
Mrs Gail Durbridge
Dr Devakar Epari
Dr Ben Fitzgerald
Dr Simon Fleming
Dr Glenn Francis
A/Prof John Fraser
Dr Bruce Garlick
Dr Andrea Garrett
Dr Troy Gianduzzo
Mrs Vhari Geary
Dr Glen Gole
A/Prof Nicholas Graves
Dr Judith Greer
Prof Sean Grimmond
Dr Alexander Guminski
A/Prof Louise Hafner
Dr Sandi Hayes
Prof Robert Hess
Ms Rosemary Higgins
Dr Andrew Hills
Mr Steven Hocken
Dr John Hooper
Ms Pam Horsley
Ms Yui Hung
Dr Wilhelmina Huston
Prof Dietmar Hutmacher
Dr Flavia Huygens
Dr Helen Irving-Rodgers
Mr Robert Isaac
Dr Monika Janda
Dr Richard Kahler
Prof David Kavanagh
Dr Richard Knight
Dr Christine Knox
Dr Srinivas KondalsamyChennakesavan
Dr Peter Kruger
A/Prof David Leavesley
Dr Paul Leo
Dr James Lefevre
Ms Deborah Lennon
Dr John Lumley
Mr Rowan Macaulay
A/Prof Christopher Maher
Dr Kerry Manton
Ms Elyse Matsen
Dr Nicole McCarthy
Prof Pamela McCombe
Mrs Sally McCracken
Ms Sandra McKellar
Dr Katie McMahon
A/Prof Nigel McMillan
Prof Kerrie Mengersen
Prof Grant Montgomery
Dr John Morgan
Dr Stephen Morrison
Ms Lynda Moynahan
Prof Kathy Mullen
Dr James Nicklin
Prof Andreas Obermair
Dr Jodie Painter
Dr Michelle Palmer
Dr Jennifer Paratz
Dr Rob Parkinson
Dr Ranald Pascoe
Dr Elise Pelzer
Dr Pamela Pollock
Prof James Quigley
Prof Ron Quinn
Dr Stephen Read
Dr Mark Richardson
Dr Katherine Robinson
Ms Hildegard Reul-Hirche
Dr Barbara Rolfe
Dr Siamak Saifzadeh
Dr Noel Saines
A/Prof Nicholas Saunders
A/Prof Greg Scalia
Dr Corina Schmid
Prof Michael Schuetz
Prof Paul Scuffham
Dr Anthony Smith
Dr Scott Sommerville
Dr Esben Strodl
Dr Dennis Taaffe
Dr Christina Theodoropoulos
Dr Ken Thistlethwaite
Dr Leslie Thompson
Dr Jamie Trapp
Dr Graham Tronc
Prof Zee Upton
Ms Sophie Van Hees
Dr Bala Venkatesh
Mrs Kate Wanstall
A/Prof Leigh Ward
Dr Mary Waterhouse
Ms Adrienne Weymouth
Dr Adam Winning
Dr Mia Woodruff
Prof David Wong
Dr Marian Worcester
Dr Margaret Wright
Ms Jane Wyatt
Clinical Trials Investigators
Dr Colin Armstrong
Dr Caroline Airey
Dr Geoff Beadle
Dr Ian Bennett
Dr Jessica Campbell
Dr Stephen Cox
Dr David Cross
Dr Robert Fathi
Dr John Feenstra
Dr Kerryn Green
Dr Mary Kelleher
Dr Terry Mau
Dr Pamela McCombe
Dr Stephen Pavia
Dr Andrew Pearson
Dr Karen Phillips
Dr Chris Pyke
Dr Tony Rafter
Dr Noel Saines
Dr Andrew Scott
Dr Scott Sommerville
Dr Julie Todhunter
A/ Prof Owen Ung
Dr Bala Venkatesh
Dr David Walker
Dr Neil Wetzig
Dr David Wilkinson
Tissue Bank Surgeons
Dr Reza Adib
Dr John Allan
Dr Melissa Buttini
Dr Peter Campbell
Dr John Chenworth
Dr William Cockburn
Dr Stephen Cook
Dr Ian Dickinson
Dr Andrea Garrett
Dr Troy Gianduzzo
Dr Boon Kua
Dr John Lumley
Dr Ian Martin
Dr Brian Meade
Dr James Nicklin
Dr Nicholas O’Rourke
Dr Christopher Pyke
Dr Scott Sommerville
Dr Les Thompson
Dr Graham Tronc
Dr Ross Turner
Dr Petar Vujovic
Dr David Walker
Dr Neil Wetzig
Tissue Bank Researchers
Dr Judith Clements
Dr Ying Dong
Allison Eckert
Assoc Prof John Hooper
Dr Wilhelmina Huston
Dr Helen Irving-Rodgers
Prof. Sunil Lakhani
Amanda McGuire
Prof Grant Montgomery
Mythily Mariasegaram
Dr Elise Pelzer
Dr Ray Wilkinson
Prof David Walker
Dr Trina Yeadon
26
WRI ANNUAL REPORT 2011-2012
Staff
(as at July 2012)
Executive
Clinical Trials Centre Staff
Tissue Bank Staff
Operations Staff
Prof Julie Campbell AO
Dr Colin Armstrong
Ms Kylie Mapledoram
Ms Rosena Crawford (maternity leave)
Dr Greg Hafner
Ms Helen Branagan
Ms Rachael Newman
Ms Deborah Gietzel
Dr Jessica Campbell
Ms Emma Raymond
Ms Georgina Gill
Investigative-Research Staff
Ms Naomi DeFazio
Data Management Staff
Mr Rod Knapp
Ms Alicia Allan
Ms Sandi Govenlock
Ms Mandy Cassimatis
Ms Ria Halstead
Ms Melanie de Jong
Ms Elaine Robertson
Ms Annette Ganter
Ms Stephanie Hoskin
Ms Deborah Lennon
Ms Catherine Rogers
Ms Jane Mooney
Dr Mary Kelleher
Ms Kate Wanstall
Dr Elise Pelzer
Ms Nieves Macias
Dr Andrew Pearson
Ms Brenda Rosser
Ms Lynne Smith
Dr Julie Todhunter
Ms Stacey Van Dyk
Ms Helen Woodhouse
Ms Jessica Meier
WRI ANNUAL REPORT 2011-2012
27
Patrons, Ambassadors and Committee Members
The Institute’s patrons, ambassadors and committee members provide endorsement, advocacy and guidance in their individual areas of expertise.
WRI is grateful for their continued interest and encouragement in the research conducted at the Institute during the 2011-12 financial year.
Patrons
Finance and Audit Committee
Governor-General Ms Quentin
Patient Outcome Research
Committee
Bryce AC, CVO (Chief Patron)
Ms Lin Bates
Dr Greg Hafner
Prof Noel Caplice
Mr Callan Battley
Ms Jillian Richards (Chair)
Ms Leneen Forde AC
Dr Judith Bauer
Ms Elaine Robertson
Prof Göran K Hansson
Dr Chris Beck
Mr Gerry Wyvill
Mr Harold Mitchell AC
Prof Julie Campbell AO
Reverend The Hon. Dr Gordon Moyes AC
Dr John Feenstra
Mr Bill Brett Senior
Ms Annette Ganter
Mr Peter Allen
Prof Judith Ann Whitworth AC
Dr Greg Hafner
Mr Chris Barnard (Chair)
Dr Luis Prado
Ms Rosena Crawford
Dr Christian Rowen
Dr Greg Hafner
Ms Sonya Vargis
Ms Jillian Richards
Ms Kate Wanstall
Ms Elaine Robertson
Dr Mary Waterhouse
Development Committee
Ambassadors
Ms Sofie Formica
Mr Guy Leech
Mr Rod Young
Prof Patsy Yates (Chair)
Ms Rosena Crawford
Investment Committee
Dr John Allan
Research Committee
Ms Wendy Zernike
Dr Geoff Beadle
Tissue Bank Management Committee
Mr Chris Barnard
Dr Geoff Beadle
Dr Greg Hafner
Prof Julie Campbell AO
Ms Teena Jameson
Dr Greg Hafner (Chair)
Mr Rod Knapp
Dr John Hooper
Mr Collin Myers (Chair)
Dr Douglas Killer
Mr Mario Pennisi
Ms Emma Raymond
Mr Charlie Sartain
Prof Julie Campbell AO
Dr Zandy Clavarino
Dr David Cross
Dr Ian Dickinson
Dr John Hayes
Prof Pam McCombe (Chair)
Prof Kerrie Mengersen
Dr Bala Venkatesh
Dr Janet Wanstall
Mr John Rowell
Dr Hemamali Samaratunga
Prof David Whiteman
Prof Patsy Yates
Secretariat: Ms Annette Ganter
Note: This list includes people who have served on a committee during the 2011-12 period.
Mr Peter Allen
28
WRI ANNUAL REPORT 2011-2012
Supporters
WRI would like to acknowledge the generosity of many individuals and companies who have supported its work over the course of the 2011-12
financial year, for which we are extremely grateful. Enabled by the generosity of these individuals and organisations, WRI has achieved unprecedented
levels of growth in terms of research programs, facilities and equipment.
Individuals and Private Foundations
Supporting Organisations
The Albrecht Foundation
Dr John Allan and Dr Janet Allan
Mr Peter Allen and Mrs Anne Allen
The Simon Axelsen Memorial Fund
Mr Trevor Bailey and Mrs Donna Bailey
The Edward Bullock Gift Fund
Justin Cameron Cancer Care Foundation
Estate of Cathryn Janet Christensen
Mr Paul Darrouzet
Dr Jon Douglas AM and Mrs Kay Douglas
Mrs Dell Dunn
Mr Wal Edgar
Dr Paul Eliadis
Prof Colin Furnival and Dr Isobel Furnival
Mr David Graham and Mrs Andrea Graham
The Greatorex Foundation
Mr Alistair Gow
Mr William Jameson and Dr Marie Jameson
Mr Douglas Logan
The Jeff McCamley Memorial
McGarry and Partners
The Atlantic Philanthropies
Grants
Mr John Martin
Queensland Government
American Medical Incorporated
Dr Alan Porter and Mrs Lois Porter
Mitsubishi Development Pty Ltd
Australian Research Council Linkage to QUT
Dr Noel Saines
Leyshon Group
Hannah’s Chance Foundation
The Sartain Family Endowment
Devine Group
National Breast Cancer Foundation
The Cecil and Eleanor Sinnamon Foundation
Xstrata
National Health & Medical Research Council
Mrs Maureen Stevenson and Mr Barry Stevenson
The Wesley Hospital Auxiliary
National Heart Foundation
Mr Neil Summerson and Mrs Jenny Summerson
Channel Seven Brisbane
Cancer Council Queensland
Mr Norman R Thompson
Ventyx (Mincom)
Slater & Gordon Lawyers
Mr John Thorsen and Mrs Wendy Thorsen
J J Richards & Sons
Mrs Marjorie Trundle
Private Portfolio Managers
The White Foundation
Rotary Club of Mirani Inc
Dr Stephen Yelland
Scouts Queensland
WRI ANNUAL REPORT 2011-2012
29
Naming Sponsors
The following individuals and organisations have sponsored rooms and equipment within WRI facilities. The Institute thanks these supporters for
their invaluable contribution.
Health and Medical Research Centre
Made possible by core funding from the Queensland
Government, the Wesley Research Institute’s Health
and Medical Research Centre was opened in
October 2009. John and Wendy Thorsen
Women’s Health Laboratory
David and Maree Alcorn
Women’s Health Research Office
Jeff McCamley Memorial
Men’s Health Research Office
White Foundation
Seniors’ Health Research Office
Mitsubishi Development Pty Ltd
Rural and Remote Health Centre
Justin Cameron Cancer Care Foundation
Wound and Bone Healing Research Office
Wesley Hospital Auxiliary
Nutrition Services Research Office Cecil and Eleanor Sinnamon Foundation
Nursing Research Centre
Simon Axelsen Memorial Fund
Research Library
Jon Douglas
Auditorium
Harold Mitchell
Conference Room
Clinical Trials Centre
Albrecht Foundation
WRI Director’s Office
JJ Richards & Sons Pty Ltd
Chief Operations Office
Corporate Express
Fundraising Office
Hannah’s Chance Foundation
Sarcoma Research Office
KPMG
Cancer Research Office
Mariart Design
Cardiovascular Research Office
Australasian Hyperbaric & Diving
Medicine Research Trust
Rehabilitation Research Office
TAA Connect
Respiratory Research Office
Wesley Corporate Health
Preventative Health Research Office
NR Solutions
Tissue Bank Research Office
The outstanding reputation of the WRI’s Clinical
Trials Centre is attracting more national and
international clinical trials to Queensland. The
sponsored facilities include:
Four consulting rooms, sponsored by the Wesley
Hospital Auxiliary
The Joan Webber Consulting Room
The Lady Mary Thomson Consulting Room
The Bau Earle Consulting Room
The Members of The Wesley Hospital Auxiliary
Consulting Room
The Justin Cameron Cancer Care Foundation
Pathology Room
Tissue Bank
Ventyx (Mincom) Wesley Research Institute
Tissue Bank
30
WRI ANNUAL REPORT 2011-2012
Community Engagement Activities
Achievements Function – Researchers of the Year Award 2011
Two Brisbane doctors who have assisted thousands of infertile couples to have children, Dr John Allan and his
wife Dr Janet Allan, are the Wesley Research Institute’s ‘Researchers of the Year’ for 2011.
The Director of the Wesley Research Institute, Professor Julie Campbell, presented the joint award at the WRI
Achievements Function, held each year to recognise the work of the Institute’s researchers.
Dr John Allan is the Director of the Wesley Reproductive Medicine and Gynaecological Surgery Unit at The
Wesley Hospital, and the Medical Director of Wesley Monash IVF. Fellow Wesley Hospital clinician Dr Janet
Allan works in clinical partnership with her husband.
The Hon Andrew Fraser MP, was a guest at the function attended by WRI researchers and supporters. Mr
Fraser congratulated all researchers for their achievements and commitment to medical research.
Professor Campbell said both Drs John and Janet Allan had well-earned reputations for improving male and
female fertility through research and clinical practice.
Drs John and Janet Allan.
Drs John and Janet Allan commenced the IVF program at the Wesley Hospital in 1988, and since then have
been driving forces in the treatment of patients undergoing assisted reproductive technology. Currently their
main focus is infertility and IVF. As well as performing clinical duties, they train medical students from the
University of Queensland and Griffith and Bond Universities in gynaecology and infertility through a teaching
program they established. Dr John Allan is also a member of the UnitingCare Health Human Research Ethics
Committee and the WRI Board.
The Researcher of the Year Award recognises the innovative research of both Drs John and Janet Allan. Since
1999, they have undertaken eight research projects through the WRI. Their work together includes research
into the effect of Chlamydia and Ureaplasma on both male and female infertility.
Guests attend presentation for 2011 Researchers of
the Year Award.
WRI Advocates – Rosalie Martin Event Series
WRI Young Advocates
WRI is committed to regularly connecting with its supporters and advocates
through quarterly Rosalie Martin Event Series functions. These events have
continued to grow in popularity throughout the year, with upwards of 70 guests
regularly attending to learn about WRI’s research studies and achievements.
The WRI Young Advocates committee was formed mid 2011 by a group of
young professionals attending the Rosalie Martin Event Series functions. The
committee is focused on organising events aimed at 25 to 35 year olds to
raise awareness for WRI and encourage interest in medical research.
The following guest speakers were welcomed to present throughout the year,
providing updates of their associated research projects:
Their inaugural fundraising event was held on 16 August at the Judith Wright
Centre, Fortitude Valley. Guests enjoyed great food, prizes and outstanding
entertainment including contemporary circus acts by Circa and burlesquestyle performances by the Candy Shop Show girls.
September 2011 Mr Cameron McDonald and Dr James Nicklin
Women’s Health
November 2011
Prof David Kavanagh, Ms Alicia Allan and
Ms Mandy Cassimatis
Rural and Remote Health and Dementia Care
March 2012
Dr Mark Richardson and Dr Liliana Endo-Munoz
Orthopaedics
May 2012
Dr Scott Crowe and Dr John Hooper
Cancer
On 30 May 2012, the Young Advocates held a movie night as their second
fundraising event. The evening was extremely successful.
WRI ANNUAL REPORT 2011-2012
Nobel Laureate at WRI
At the invitation of the WRI Director, Prof Julie Campbell, the 2009 Nobel
Laureate for Physiology or Medicine Professor Elizabeth Blackburn presented,
on Tuesday 19 June at the WRI, her only seminar to senior clinicians and
scientists during her three week visit to Australia.
31
Professor Campbell was also the organizer of Professor Blackburn’s series of
talks, called ‘Hooked on Science’, to high school students in Brisbane, Sydney,
Canberra, Melbourne and Hobart to inspire them to take an interest in science
and maths in senior high school.
Professor Blackburn is the first female Australian to win a Nobel Prize.
Prof Blackburn’s talk encompassed her Nobel Prize-winning research into
telomeres (the ends of chromosomes) and the activity of the enzyme telomerase
(that prevents telomeres from shortening too much after each cell division) to
the development of diseases such as cancer and heart disease that impact life
expectancy.
Also in attendance was WRI Chief Patron Her Excellency Governor-General Ms
Quentin Bryce AC CVO, Assistant Minister for Health Dr Chris Davis MP and Dr
David Kennedy from Atlantic Philanthropies.
“We are indeed honoured to have Prof Elizabeth Blackburn at the Wesley
Research Institute,” Prof Julie Campbell said.
“To host a Nobel Laureate gives the WRI enormous pride and inspiration,” said
WRI Chairman Mr Martin Albrecht.
From left: Prof Elizabeth Blackburn, Her Excellency Governor-General Ms Quentin
Bryce AC CVO and Prof Julie Campbell.
Xstrata Copper Funds Vital Research to Improve Health
and Quality of Life of Mining Company Employees
On 28 May, 2012 Xstrata announced $900,000 in funding over three years for
the Wesley Research Institute to commence a research program focused on
improving the health and wellbeing of the mining workforce and regional mining
communities.
The announcement was made at a special event at WRI attended by Mr Steve
de Kruijff, Chief Operating Officer for Xstrata Copper North Queensland, Peter
Allen, Deputy Chairman of WRI, and Professor Julie Campbell, Director of WRI.
Also in attendance were Assistant Minister for Health Dr Chris Davis MP, and
Assistant Minister for Technical and Further Education Saxon Rice MP, with
Channel Seven Presenter and WRI Ambassador Rod Young as Master of
Ceremonies.
From left: Mr Steve de Kruijff, CEO Xstrata Copper NQ (left) and Mr Peter Allen WRI
Deputy Chairman with MC and WRI Ambassador Mr Rod Young.
Mr de Kruijff said it was hoped that the research program could make a
valuable contribution to the overall health of mining workers.
“The scope of the research is to initially concentrate on two areas of high
priority to Xstrata – assisting injured workers through various emotional
aspects of their recovery process and improving the ongoing quality of life for
mine workers after they retire.
“We know from previous partnering with WRI that they draw on an enormous
range of health, medical and scientific expertise. They concentrate on very
practical clinical research aimed at immediate improvements in the care of
people and their quality of life. We are confident that this program of research
will not only produce early results but also lead to other research projects that
will benefit both our people and the communities in which they work and live.”
The Director of WRI, Professor Julie Campbell AO, said that an experienced
researcher, Dr Tamara Street, had already been appointed to manage the
program.
From left: Assistant Minister for Health Dr Chris Davis MP and Assistant Minister for
Technical and Further Education Saxon Rice MP with Prof Julie Campbell and Mr Rod
Young.
32
WRI ANNUAL REPORT 2011-2012
Financials
Summary of Financial Information Income and Expenditure for the 2011-12 year.
2012
2011
1,150,304
1,343,559
Clinical trials and other non-grant income
988,990
794,682
Research grants
235,138
204,365
Qld State Government operating grant
250,000
272,500
UnitingCare Health operating grant
113,491
110,476
Investment distribution income
909,772
1,131,488
-
140,889
Smart State Loan income
282,167
-
Gain on sale of available-for-sale investments
204,227
250,343
Other income
216,935
87,207
4,351,024
4,335,509
Research funding expenses
953,956
1,206,137
Research services expenses
1,752,363
1,924,553
Administration expenses
816,152
789,853
Occupancy expenses
610,105
523,376
Fundraising and marketing expenses
362,981
443,500
-
140,889
77,047
79,578
-
325,693
200,519
179,520
4,773,123
5,613,099
-422,099
-1,277, 590
266,358
-86,544
Retained earnings at the beginning of the financial year
18,879,683
20,243,817
Retained earnings at the end of the financial year
18,723,942
18,879,683
Revenue
Gifts, bequests, donations and sponsorships
Sponsored advertising revenue (in-kind)
Total Revenue
Expenses
Sponsored advertising expenses (in-kind)
Investment related expenses
Loss on sale of available-for-sale investments
Other expenses from ordinary activities
Total Expenses
Operating surplus/(loss) from ordinary activities
Net appropriation from/(to) capital reserves
WRI ANNUAL REPORT 2011-2012
33
Future
Following the retirement of the current Director Prof Julie Campbell AO, and with the commencement in January 2013 of her replacement Prof
Christian Gericke, it is expected that the WRI will continue to encourage, facilitate and fund medical research that leads to an improvement in
patients’ lives.
Investigative Research
Tissue Bank
Professor Gericke is a neurologist whose research interests are health services
delivery and public health. It is expected that WRI’s research armamentarium
will expand to include these disciplines while continuing to include all aspects of
medicine and of patient improvement.
In 2013 the Ventyx WRI Tissue Bank will:
Clinical Trials Centre
The Clinical Trials Centre has now established an international reputation as
a centre of excellence and has worked with most of the large international
pharmaceutical companies and Clinical Research Organisation (CROs) to
investigate a variety of new medical treatments and devices.
The future vision for the Clinical Trials Centre is to expand its clinical services
and continue to increase the number and quality of research collaborations,
partnerships and networks.
Particular focus will be given to identifying and targeting cost-effective clinical
trials to fully utilise the Centre’s core strengths and facilities.
This is heavily reliant on identifying best-practice strategies to increase
participant recruitment rates and enhance community engagement in the
research process.
• Continue providing a wide range of samples and services to researchers
both in Queensland and nationally
• Increase distribution to an international stage
• Continue to expand current sample collections and range
• Continue to establish long-term partnerships and collaborations with keystakeholders including surgeons, pathology companies, government bodies,
researchers and tertiary institutes
• Continue to help researchers reach their goals sooner, by supplying high
quality clinically annotated samples
The long-term future vision for the Ventyx WRI Tissue Bank is to create a
bionetwork of Tissue Banks for Queensland, similar to the Victorian Cancer
Biobank Consortium.
This scheme would not only increase the number of people able to donate their
excess tissue samples to medical research, but save Queensland researchers
even more time and money.
Notes